BioSpace News Archive

BrainStorm Cell Therapeutics Inc. announced that Partners MS Center at Brigham and Women’s Hospital, a leading research and clinical care center, has contracted with BrainStorm as a clinical study site for the Company’s Phase 2 open-label, multicenter study of repeated intrathecal administration of NurOwn® in participants with progressive Multiple Sclerosis.

Inflazome, the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, announces the successful completion of a Phase I study of its investigational drug, Somalix.

Submission based on data from the Phase III PRIMA clinical study that demonstrated clinically meaningful outcomes of niraparib maintenance treatment in the first-line setting regardless of biomarker status

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced today that management will present at the following upcoming investor conferences:

COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 8,461,540 shares of its common stock at a price of $1.30 per share, for aggregate gross proceeds of approximately $11.0 million, in a registered direct offering priced at-the-market under Nasdaq rules